<?xml version="1.0" encoding="UTF-8"?>
<p>Routine blood examination should be emphasized in the management of patients during chemotherapy intermission to monitor the extent of myelosuppression through the important concerns including leukocyte counts, neutrophils, platelets, and red blood cells and hemoglobin levels. Mild‐to‐moderate myelosuppression can be treated with corresponding oral drugs. However, the following conditions need to be treated under medical guidance: leukocyte count &lt;2.0 × 10
 <sup>9</sup>/L, neutrophil count &lt;1.0 × 10
 <sup>9</sup>/L, or infection symptoms such as fever, frequent urination, and abnormal vaginal secretions in women; platelet count &lt;50 × 10
 <sup>9</sup>/L, or the occurrence of gum/nose bleeds and skin congestion; hemoglobin level &lt; 100 g/L, or pale appearance, fatigue, anorexia, etc.
</p>
